OBI-221

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameOBI-221

Drug Alias NameOBI-221OBI221

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Hepatocyte growth factor receptorAnti-Receptor tyrosine-protein kinase erbB-3

TargetsHepatocyte growth factor receptorReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesObi Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesObi Pharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A